Sanyou Biopharmaceuticals is a high-tech biopharmaceutical company driven by the mission of “To make it easy to develop new drugs worldwide”. Guided by the vision “To become a front-runner in global innovative drug R&D”, the company focuses on the R&D and commercialization of innovative drugs.

Built on its AI-STAL and Sanyou AI-Drug Accelerator (SAI-DA) platforms and driven by its innovative drug pipeline, Sanyou is committed to fundamentally addressing the key challenges at the source of innovative drug development.

Sanyou Bio has been dedicated to developing a world-class innovative biological drug R&D hub and to working collaboratively with partners worldwide to accelerate the development of innovative therapeutics.

Headquartered in Shanghai, China, Sanyou has established global business centers across Asia, North America, and Europe, forming an international business network. The company currently operates and has planned over 20,000 square meters of R&D and GMP facilities.

Sanyou has established strong partnerships with more than 2,000 pharmaceutical and biotechnology companies worldwide. It has signed over 100 collaborative R&D agreements and completed more than 3,000 drug discovery and development projects. More than 10 CPO programs have entered clinical development, including four that have reached Phase III clinical trials.

The company has filed over 180 invention patents, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.